Updated results for an ongoing study showcase the viability of treating hepatitis C virus (HCV) with imported, and thereby more affordable, generic versions of direct-acting antivirals. Results are not in for all 1,087 participants in this multinational cohort, but researchers at Australia's University of Tasmania say the data so far are promising. They report that sustained virologic response (SVR) after 4 weeks was observed in 94% of 523 patients who took generic versions of sofosbuvir, ledipasvir, daclatasvir, or velpatasvir imported from Bangladesh, China, Egypt, and India. Week 12 data for 450 patients, further, revealed SVR in 89%. "If quality controls are in place, I think there is no doubt that generic direct-acting antivirals will help cure patients in areas where currently approved combinations are not available or are restricted," speculated study lead James Freeman, MD. "We could treat 68 million people with [HCV] and spend the same amount as we spend to treat one person with HIV for 1 year." Unfortunately, he added, generic direct-acting antivirals are not due to land in the United States for another 15 years.